Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.
about
Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial InfectionsIntegrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.Comparative clinical study of conjunctival toxicities of newer generation fluoroquinolones without the influence of preservatives.Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis.Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
P2860
Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Concentrations of besifloxacin ...... topical ocular administration.
@ast
Concentrations of besifloxacin ...... topical ocular administration.
@en
type
label
Concentrations of besifloxacin ...... topical ocular administration.
@ast
Concentrations of besifloxacin ...... topical ocular administration.
@en
prefLabel
Concentrations of besifloxacin ...... topical ocular administration.
@ast
Concentrations of besifloxacin ...... topical ocular administration.
@en
P2093
P2860
P356
P1476
Concentrations of besifloxacin ...... topical ocular administration
@en
P2093
Aron Shapiro
Gail Torkildsen
Joel W Proksch
Stephanie K Lynch
Timothy L Comstock
P2860
P304
P356
10.2147/OPTH.S9163
P407
P577
2010-04-26T00:00:00Z